肠道微生物在非小细胞肺癌免疫治疗中的研究进展  

Research progress of gut microbes in immunotherapy of non-small cell lung cancer

作　　者：李飞扬 陈越 刘颖[1] 胡舒怡 沈波[1] 方瑛 周国仁[1] LI Feiyang;CHEN Yue;LIU Ying;HU Shuyi;SHEN Bo;FANG Ying;ZHOU Guoren(Department of Medical Oncology,The Affiliated Cancer Hospital of Nanjing Medical University,Jiangsu Institute of Cancer Research,Jiangsu Cancer Hospital,Nanjing,Jiangsu 210009,China)

机构地区：[1]南京医科大学附属肿瘤医院江苏省肿瘤防治研究所江苏省肿瘤医院肿瘤内科,江苏南京210009

出　　处：《中国临床研究》2025年第3期339-344,共6页Chinese Journal of Clinical Research

基　　金：南京市2023年度科技发展计划生命健康科技专项(202305027)。

摘　　要：免疫检查点抑制剂显著改善了非小细胞肺癌(NSCLC)患者的临床预后,特别是细胞程序性死亡-配体1高表达且驱动基因阴性的晚期NSCLC。但是仍有部分患者不能获益于免疫治疗,因而需继续探索能有效预测NSCLC免疫治疗疗效的生物标志物。肠道微生物(GM)是人一生中持续暴露的环境因素,研究发现特定GM与多种实体瘤(包括NSCLC)免疫治疗的良好预后密切相关。本文对GM及其代谢产物在NSCLC免疫治疗中的预后作用进行综述,意在筛选适合NSCLC免疫治疗的人群并为肿瘤精准治疗提供新的模式。Immune checkpoint inhibitors have significantly improved the clinical prognosis of patients with non-small cell lung cancer(NSCLC),especially advanced NSCLC with high expression of programmed cell death ligand 1 and negative driver genes.However,there are still some patients who cannot benefit from immunotherapy,so it is necessary to explore more biomarkers that can effectively predict the efficacy of immunotherapy in NSCLC.Gut microbiome(GM)is an environmental factor that people are continuously exposed to throughout their lives.Studies have found that specific GM is strongly associated with a good prognosis of immunotherapy for a variety of solid tumors,including NSCLC.This article reviews the prognostic effects of GM and its metabolites in NSCLC immunotherapy,aiming to screen the population suitable for NSCLC immunotherapy and offering a new pattern in precision tumor treatment.

关 键 词：非小细胞肺癌 肠道微生物 程序性死亡受体-1 程序性死亡受体配体-1 免疫治疗 肠道菌群移植 

分 类 号：R734.2[医药卫生—肿瘤]